New hope for lung cancer patients: drug combo targets treatment resistance

NCT ID NCT07158489

Recruiting now Disease control Sponsor: Swiss Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study tests a new combination of two drugs—gemcitabine (chemotherapy) and ivonescimab (a targeted therapy)—in people with advanced non-small cell lung cancer whose disease got worse after standard immunotherapy. The goal is to see if this combination can shrink tumors or stop them from growing. About 47 participants will receive the treatment, and researchers will measure how many respond. This is a phase 2 trial, meaning it's still early but could lead to better options for patients who have run out of effective treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Hôpital Fribourgeois - Hôpital Cantonal
RECRUITING

Fribourg, Switzerland
Hôpitaux Universitaires de Genève
RECRUITING

Geneva, 1211, Switzerland
IOSI Ospedale Regionale di Bellinzona e Valli
RECRUITING

Bellinzona, 6500, Switzerland
Kantonsspital Baden
RECRUITING

Baden, 5404, Switzerland
Kantonsspital Graubuenden
RECRUITING

Chur, CH-7000, Switzerland
Kantonsspital Winterthur
RECRUITING

Winterthur, 8401, Switzerland
Universitätsspital Basel
RECRUITING

Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.